European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
The European Commission (EC) has given conditional marketing authorization to the new histone deacetylase (HDAC) inhibitor Duvyzat (givinostat), Italfarmaco announced on 6th June. When...
EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy
The European Medicines Agency (EMA) has suggested that Duvyzat (givinostat) be given a conditional marketing authorization in the EU to treat Duchenne muscular dystrophy...
NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera
AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne...
Vamorolone (Agamree) Approved in Scotland
The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for...
What is Agamree (vamorolone)? What is Agamree Used For?
We will answer your questions such as what is AGAMREE (Vamorolone), which is used in the treatment of Duchenne Muscular Dystrophy (DMD) and is...